Strategic Pharmacovigilance for Biosimilars

As biosimilars are complex biologics with potential variability in immunogenicity, efficacy, and perception, sponsors must adopt a proactive, lifecycle-focused pharmacovigilance strategy. The focus is shifting from reactive post-marketing safety activities to strategic, technology-enabled pharmacovigilance that supports global compliance, builds stakeholder trust, and enables long-term commercial success.

Read this guide to explore more about:
– Why biosimilars need specialized pharmacovigilance
– Strengthening signal detection and immunogenicity monitoring
– Using scalable, automated PV systems globally
– Building clinician and patient confidence with real-world evidence